Our Science
OUR SCIENCE
Publications
This section includes publications related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets.* View our congress presentations here.
publication
September 19, 2024
Cell Chemical Biology
New Therapies on the Horizon: Targeted Protein Degradation in Neuroscience
July 29, 2024
Future Oncology
VERITAC-2: A Phase III Study of Vepdegestrant, a PROTAC ER Degrader, Versus Fulvestrant in ER+/ HER2- Advanced Breast Cancer
May 31, 2024
Clinical Cancer Research
Oral Estrogen Receptor PROTAC® Vepdegestrant (ARV-471) is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or P13K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models
May 23, 2024
BMC Cancer
Systematic Literature Review of Real-World Evidence for Treatments in HR+/HER2- Second-line LABC/mBC After First-line Treatment with CDK4/6i
January 5, 2024
J Med Chem
PROTACs Targeting BRM (SMARCA2) Afford Selective in Vivo Degradation over BRG1 (SMARCA4) and are Active in BRG1 Mutant Xenograft Tumor Models
January 4, 2024
Nature Structural & Molecular Biology
Co-Opting the E3 Ligase KLHDC2 for Targeted Protein Degradation by Small Molecules
June 6, 2023
Journal of Medicinal Chemistry
Physicochemical Property Determinants of Oral Absorption for PROTAC® Protein Degraders
February 13, 2023
Nature Reviews Clinical Oncology
Protein Degraders Enter the Clinic – A New Approach to Cancer Therapy
January 18, 2022
Nature Reviews Drug Discovery
PROTAC Targeted Protein Degraders: The Past is Prologue
* Vepdegestrant (VEPPANU™) is licensed to Rigel Pharmaceuticals, which holds the exclusive global development, manufacturing, and commercialization rights.